How does misoprostol compare to dinoprostone for cervical ripening?

Comment by InpharmD Researcher

Literature suggests that misoprostol may be more effective at achieving cervical ripening and inducing labor; however, some data indicate that misoprostol may be associated with a higher incidence of uterine hyperstimulation and tachysystole compared to dinoprostone. Thus, the choice between misoprostol and dinoprostone should consider both efficacy in induction and the potential risk of hyperstimulation and tachysystole.
Background

According to an American College of Obstetricians and Gynecologists (ACOG) practice bulletin, two prostaglandin E2 (PGE2) preparations are commercially available: a gel in a 2.5 mL syringe containing 0.5 mg of dinoprostone (Prepidil®) and a vaginal insert containing 10 mg of dinoprostone (Cervidil®), of which both are FDA approved for cervical ripening in women at or near term. Compared with placebo or oxytocin alone, vaginal prostaglandins used for cervical ripening have been observed to increase the likelihood of delivery within 24 hours, but with an increase of uterine tachysystole with associated fetal heart rate (FHR) changes and without a reduction in the rate of cesarean delivery. Misoprostol administered intravaginally has been reported to be either superior to or as efficacious as dinoprostone gel. Additionally, misoprostol has been found to cause less use of epidural analgesia, more vaginal deliveries within 24 hours, and more uterine tachysystole with or without FHR changes compared with dinoprostone and oxytocin. [1]

It is stated that the benefits of using oral misoprostol for labor induction are that it is low in cost, noninvasive, stable at room temperature, and is associated with lower cesarean rates than other induction methods. Additionally, it may lead to less uterine hyperstimulation with FHR changes as compared to vaginal misoprostol. However, despite its’ benefits, it notes that the optimal dose for safety is yet to to be determined. Compared to the oral route, benefits of vaginal misoprostol are similar with additional benefit of achieving a higher plasma level. It also is stated to be more efficacious at cervical ripening and induction of labor compared to oxytocin and dinoprostone. However, it is noted that vaginal misoprostol is associated with more uterine hyperstimulation and meconium-stained fluid when compared to other vaginal induction methods. Furthermore, slow or erratic absorption can occur with vaginal misoprostol, which may result in inaccurate dosing. A stated advantage of using dinoprostone vaginal insert is that it is able to be removed quickly in the case of FHR changes, which may resolve within 15 minutes after removing the insert. It is noted, however, that vaginal dinoprostone is associated with a 5% chance of uterine hyperstimulation one hour after administration. [2]

A 2024 systematic review and meta-analysis examined the efficacy and safety of intravaginal misoprostol compared to dinoprostone for labor induction at term. This analysis involved eight randomized controlled trials (RCTs) with a total of 1,801 participants, including 937 women in the misoprostol group and 864 in the dinoprostone group. The study population consisted of singleton pregnant women with live intrauterine gestations and unfavorable cervices, ranging from 37 to 42 weeks of gestation. The primary objective was to analyze key maternal and neonatal outcomes, such as the rates of vaginal delivery within 24 hours, cesarean delivery, and the necessity for oxytocin augmentation. Misoprostol was associated with a significantly reduced need for oxytocin augmentation compared to dinoprostone (risk ratio [RR] 0.83; 95% confidence interval [CI] 0.71 to 0.97; p= 0.02). However, other outcomes, including cesarean delivery rates, uterine tachysystole, hyperstimulation, NICU admissions, and APGAR scores, showed no significant differences between the two groups, suggesting similar safety and efficacy profiles. Notably, the analysis revealed no significant heterogeneity among studies regarding vaginal delivery within 24 hours, cesarean delivery, and instrumental delivery. Despite varying dosages and administration regimens across trials, the authors suggest that intravaginal misoprostol is an effective and safe alternative to dinoprostone for labor induction in clinical settings, offering the advantage of requiring less oxytocin augmentation. [3]

Another 2024 systematic review and updated meta-analysis involving 53 RCTs (N= 10,455 patients) assessed the efficacy and safety of oral and vaginal misoprostol compared to dinoprostone for labor induction in women. Vaginal misoprostol showed a statistically significant higher success rate for labor induction compared to vaginal dinoprostone (RR 1.14; 95% CI 1.08 to 1.21; p<0.00001; I2= 69%), with less need for additional oxytocin (RR 0.67; 95% CI 0.59 to 0.76; p<0.00001; I2= 82%). However, vaginal misoprostol was associated with a higher incidence of uterine hyperstimulation, tachysystole, and abnormal cardiotocography compared to dinoprostone. There were no significant differences in cesarean section rates or neonatal intensive care unit admissions between the groups. Interestingly, oral misoprostol was found to have comparable safety profiles to vaginal dinoprostone, providing similar efficacy without increased risks of adverse outcomes, making it a potential alternative for labor induction. These findings suggest that while vaginal misoprostol is effective, its safety profile must be carefully considered, and oral misoprostol may offer a safer, equally effective option. [4]

A 2024 individual participant data meta-analysis of randomized controlled trials examined the effectiveness and safety of induction of labor using low-dose vaginal misoprostol compared to vaginal dinoprostone. This analysis combined data from eight trials, encompassing 4,180 women (low-dose vaginal misoprostol, n= 2,077; vaginal dinoprostone, n= 2,103) to evaluate the primary outcomes, which included vaginal delivery rates, composite adverse perinatal outcomes, and composite adverse maternal outcomes. Low-dose vaginal misoprostol and vaginal dinoprostone were observed to have comparable rates of vaginal birth and similar perinatal safety profiles. Notably, use of low-dose vaginal misoprostol was associated with a significantly lower rate of composite adverse maternal outcomes compared to vaginal dinoprostone (adjusted odds ratio [OR] 0.80; 95% CI 0.65 to 0.98; p= 0.03; I2= 0%). Despite the comparable effectiveness in achieving vaginal delivery, the distinct advantage of low-dose vaginal misoprostol lies in its better maternal safety profile, characterized by a trend toward lower maternal infection rates and reduced intensive care unit admissions among participants. Overall, low-dose vaginal misoprostol may not only be a viable alternative to vaginal dinoprostone for cervical ripening and labor induction, but also offer benefits in terms of maternal safety, particularly in resource-limited settings where cost-effectiveness is crucial. [5]

Finally, a 2023 systematic review and meta-analysis synthesized data from 39 RCTs involving 15,993 participants to evaluate the safety profiles of misoprostol and dinoprostone for labor induction in women with singleton pregnancies beyond 36 weeks' gestation. Maternal outcomes analyzed included cesarean section rate, instrumental deliveries, tachysystole, uterine rupture, postpartum hemorrhage, and chorioamnionitis. Neonatal outcomes encompassed five-minute Apgar scores of less than 7, meconium-stained amniotic fluid, NICU admissions, and infant mortality. No statistically significant differences were identified between misoprostol and dinoprostone in the primary outcomes of cesarean delivery (OR 0.94; 95% CI 0.84 to 1.05) or instrumental delivery (OR 1.04; 95% CI 0.90 to 1.19). Rates of uterine tachysystole were comparable between groups overall (OR 1.21; 95% CI 0.91 to 1.60), though a subgroup analysis revealed heightened tachysystole with vaginal misoprostol compared to dinoprostone gel (OR 1.48; 95% CI 1.09 to 2.01). There was no significant difference in postpartum hemorrhage (OR 0.85; 95% CI 0.62 to 1.15), neonatal Apgar scores <7 (OR 0.83; 95% CI 0.61 to 1.12), or NICU admissions (OR 0.91; 95% CI 0.77 to 1.09). The findings suggest a comparable safety profile between the two agents, with no clear superiority for either in any maternal or neonatal outcomes. [6]

Background References: [1] American College of Obstetrician-Gynecologists. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol. 2009;114(2 Pt 1):386-97.
[2] Yount SM, Lassiter N. The pharmacology of prostaglandins for induction of labor. J Midwifery Womens Health. 2013;58(2):133-44.
[3] Lakho N, Hyder M, Ashraf T, et al. Efficacy and safety of misoprostol compared with dinoprostone for labor induction at term: an updated systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2024;11:1459793. Published 2024 Dec 9. doi:10.3389/fmed.2024.1459793
[4] Ramadan M, Bashour G, Eldokmery E, et al. The efficacy and safety of oral and vaginal misoprostol versus dinoprostone on women experiencing labor: A systematic review and updated meta-analysis of 53 randomized controlled trials. Medicine (Baltimore). 2024;103(40):e39861. doi:10.1097/MD.0000000000039861
[5] Patabendige M, Chan F, Vayssiere C, et al. Vaginal misoprostol versus vaginal dinoprostone for cervical ripening and induction of labour: An individual participant data meta-analysis of randomised controlled trials. BJOG. 2024;131(9):1167-1180. doi:10.1111/1471-0528.17794
[6] Taliento C, Manservigi M, Tormen M, et al. Safety of misoprostol vs dinoprostone for induction of labor: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2023;289:108-128. doi:10.1016/j.ejogrb.2023.08.382
Relevant Prescribing Information

Misoprostol tablet [7]

Pregnancy
Labor and delivery
The risk of uterine rupture associated with misoprostol use in pregnancy increases with advancing gestational ages and prior uterine surgery, including Cesarean delivery. Grand multiparity also appears to be a risk factor for uterine rupture.

Misoprostol should not be used in the third trimester in women with a history of Cesarean section or major uterine surgery because of an increased risk of uterine rupture. Misoprostol should not be used in cases where uterotonic drugs are generally contraindicated or where hyperstimulation of the uterus is considered inappropriate, such as cephalopelvic disproportion, grand multiparity, hypertonic or hyperactive uterine patterns, or fetal distress where delivery is not imminent, or when surgical intervention is more appropriate.

Cervidil (dinoprostone insert) [8]

Warnings and Precautions
Disseminated Intravascular Coagulation
CERVIDIL should be used with caution in women at high risk of postpartum disseminated intravascular coagulation (DIC). Physiologic or pharmacologic induction of labor, including the use of CERVIDIL, is associated with an increased risk of DIC during the postpartum period. Women aged 30 years or older, those with complications during pregnancy and those with a gestational age over 40 weeks have an increased risk of DIC during the postpartum period. As soon as possible, assess for an evolving fibrinolysis in the immediate post-partum period. Therapy consisting of prompt removal of the source of procoagulant material, replacement of depleted clotting factors and, in some cases, anti-coagulation with heparin should be instituted promptly.

Uterine Tachysystole and Uterine Hypersystole/Hypertonicity
The use of CERVIDIL may cause uterine tachysystole with or without fetal heart rate changes. While using CERVIDIL, carefully monitor uterine activity, fetal status and the progression of cervical dilatation and effacement. Remove CERVIDIL with any evidence of uterine tachysystole, uterine hypersystole/hypertonicity, fetal distress, or if labor commences. CERVIDIL is contraindicated when prolonged contraction of the uterus is detrimental to fetal safety or uterine integrity, such as previous cesarean section or major uterine surgery, because of the risk of uterine rupture and obstetrical complications (e.g., need for hysterectomy and the occurrence of fetal or neonatal death).

Prostaglandins, including CERVIDIL, may potentiate the effect of oxytocin. Remove CERVIDIL at least 30 minutes before administration of an oxytocic agent is initiated and continue to carefully monitor uterine activity. Remove CERVIDIL prior to amniotomy or following rupture of membranes because the higher vaginal pH that occurs with rupture of membranes may result in higher release rate of dinoprostone.

Relevant Prescribing Information References: [7] Misoprostol tablet. Prescribing information. ANI Pharmaceuticals, Inc.; 2024.
[8] Cervidil (dinoprostone insert). Prescribing information. Ferring Pharmaceuticals Inc.; 2023.
Literature Review

A search of the published medical literature revealed 5 studies investigating the researchable question:

How does misoprostol compare to dinoprostone for cervical ripening?

Level of evidence

C - Multiple studies with limitations or conflicting results  Read more→



Please see Tables 1-5 for your response.


 

Comparative efficacy and cost of the prostaglandin analogs dinoprostone and misoprostol as labor preinduction agents

Design

Randomized, blinded, phase III clinical trial

N=111

Objective

To compare the relative efficacy and cost of three commercially available prostaglandins (PGE), misoprostol (Cytotec), dinoprostone gel (Prepidil), and dinoprostone insert (Cervidil), as labor preinduction agents

Study Groups

Misoprostol (n=38)

Dinoprostone gel (n=35)

Dinoprostone insert (n=38)

Methods

Inclusion criteria: an unfavorable cervical Bishop score of ≤5, a singleton pregnancy with vertex presentation and no contraindication to vaginal delivery, the absence of spontaneous uterine contraction, a reactive nonstress test

Exclusion criteria: a known hypersensitivity to prostaglandins, rupture membranes, suspected chorioamnionitis, parity of >5, a previous cesarean delivery or a history of uterine surgical procedures

Patients were randomized to receive either misoprostol 50 µg every 6 hours for two doses, dinoprostone gel 0.5 mg every 6 hours for two doses, or dinoprostone insert 10 mg for one dose intravaginally. Twelve hours later, oxytocin induction was initiated via a standardized protocol.

Duration

April 1996 through August 1997

Outcome Measures

Change in Bishop score, time to complete dilation, relative cost

Baseline Characteristics

 

Dinoprostone gel (n=35)

Dinoprostone insert (n=38)

Misoprostol (n=38)

 

Age, years

28 26.7 27.9  

Body mass index, kg/m²

31.3 32 31.5  

Gestational age, weeks

39.2 39.3 39.3  

Initial Bishop score

3 3 3  

Multiparous

14 (40%) 16 (42.1%) 15 (39.5%)  

Results

 

Dinoprostone gel (n=35)

Dinoprostone insert (n=38)

Misoprostol (n=38)

P-value

Efficacy

Change in Bishop score

Time to complete dilation, h

 

2.2 ± 1.3

28.9 ± 13.1

 

3.2 ± 2.3

30.3 ± 13.3 

 

5.2 ± 3.1

22.7 ± 10.9

 

<0.0001

0.03

Relative cost

PGE preinduction per patient

1-point change in Bishop score/patient

Total cost 

 

$203.43

$136

$1572.92

 

$168.23 

$90.39

$1565.72

 

$2.37

$0.97

$1036.13

 

<0.0001

<0.0001

<0.0001

Total cost=cost of preinduction agent + cost of oxytocin + cost of labor and delivery suite/nursing

Adverse Events

There were no significant differences in regards to adverse events (eg. neonatal outcomes, postpartum hemorrhage, uterine hyperstimulation, meconium passage, chorioamnionitis) between three treatment arms.

Study Author Conclusions

Misoprostol is more cost-effective than the comparable commercial dinoprostone prostaglandin preparations as an adjuvant to labor induction in women with an unfavorable cervix.

InpharmD Researcher Critique

This study was conducted at a single institution in Michigan. This study was also conducted in the late 1990s, so prices may have changed since then.



Table 1 References:
[9] Ramsey PS, Harris DY, Ogburn PL, Heise RH, et al. Comparative efficacy and cost of the prostaglandin analogs dinoprostone and misoprostol as labor preinduction agents. Am J Obstet Gynecol. 2003;188(2):560-5.

 

A comparison of obstetrical outcomes and costs between misoprostol and dinoprostone for induction of labor

Design

Retrospective cohort study

N=331

Objective

To compare resource utilization (efficiency) and obstetrical/cost outcomes of single-dose misoprostol versus dinoprostone for induction of labor at term

Study Groups

Dinoprostone (n=276)

Misoprostol (n=55)

Methods

Inclusion criteria: induction of labor between 37 to 41 weeks’ gestation with singleton, live-born infants presenting with an unfavorable cervix (defined as a Bishop score ≤4)

Exclusion criteria: history of a previous cesarean section, known uterine abnormalities, severe preeclampsia with central nervous system involvement or hemolysis, elevated liver enzymes, and low platelet counts, fetal malpresentation, intrauterine fetal demise, known fetal anomalies

This was a retrospective review of a single institution in New York. Misoprostol was given as a single dose of 50 mcg inserted into the posterior vaginal fornix followed by oxytocin 4 hours later. Dinoprostone was given as 10mg inserted into the posterior vaginal fornix with removal after 12 hours. Additional doses of dinoprostone were used when determined clinically necessary for a maximum of 3 doses. Oxytocin was started 30 minutes after the removal of the dinoprostone insert.

Duration

January 2012 to April 2014

Outcome Measures

Length of labor and delivery stay, time to onset of active labor (defined as cervical dilatation > 4 cm), time to vaginal delivery, and average hospital cost per patient, rate of tachysystole

Baseline Characteristics

 

Dinoprostone (n=276)

Misoprostol (n=55)

P-value

Maternal age, years

30.5 ± 5.5 29.4 ± 6.6 0.204

Gravidity

Parity

1 (1-10) 

0 (0-5)

2 (1-10)

0 (0-4)

0.006

0.324

Gestational age, weeks (range)

40.3 (37-42) 39.6 (37-41) <0.001

Birthweight, g

3,456.6 ± 489.6 2,219.38 ± 391.8 0.026

Results

 

Dinoprostone (n=276)

Misoprostol (n=55)

P-value

Length of labor and delivery stay, hours (range)

24 (7-60) 16 (8-59) <0.05

Time to onset of labor, hours (range)

12.4 (0.9-51.5)

8.15 (1.6-21.2) <0.001

Time to delivery, hours (range)

17.1 (2.8-56.0)

10.68 (3.9-31.2)

<0.001

Tachysystole

25 (9.1%) 6 (10.9%) 0.667

Average hospital cost per patient

$7,176 $6,735  

The calculated cost savings with misoprostol were ~$440 per patient.

Adverse Events

N/A

Study Author Conclusions

A single dose of intravaginal misoprostol 50 mcg is more effective than dinoprostone inserts for induction of labor at term with respect to labor and delivery utilization without increasing perinatal morbidity.

InpharmD Researcher Critique

The cost analysis in this study has somewhat limited applicability outside of the specific institution where it was conducted. However, while the exact costs may differ between institutions, it remains that misoprostol is considerably less expensive than dinoprostone. The study also suggests that misoprostol has no higher incidence of tachysystole than dinoprostone, but a larger sample size would be needed to confirm this.

Limitations of this study include the retrospective study design, which allows for confounding and biases. The misoprostol group also had fewer patients than what was calculated for the power analysis. 



Table 2 References:
[10] Nadia Bennett K, Park H, Cioffi J, et al. A comparison of obstetrical outcomes and costs between misoprostol and dinoprostone for induction of labor. J Matern Fetal Neonatal Med. 2016;29(22):3732-6.

 

What can we do to reduce the associated costs in induction of labour of intrauterine growth restriction foetuses at term? A cost-analysis study

Design

Retrospective cohort study

N=150

Objective

To evaluate the costs associated with induction of labor in intrauterine growth restriction fetuses comparing different procedures

Study Groups

Misoprostol (n=24)

Dinoprostone (n=24)

Cervical ripening balloon (n=77)

Methods

Inclusion criteria: type 1 intrauterine growth retardation fetuses, cephalic presentation, gestation age >37 weeks

Exclusion criteria: multiple gestation, Bishop score >6, maternal-fetal infection, previous cesarian section or uterine surgery

This was a retrospective study of a single institution in Barcelona. Misoprostol 25 mcg was vaginally administered every 4 hours with a maximum of 4 doses. Dinoprostone 10 mg was administered via vaginal insert. Cervical ripening balloons were inserted and left for 24 hours. According to protocols, membrane rupture and oxytocin perfusion were added if the active phase of labor was not achieved within 24 h of induction.

Duration

2014 to 2016

Outcome Measures

direct costs of the method of induction, type of birth, complications, use of epidural analgesia when was requested by the patient, neonatal and maternal admission, and medication employed in childbirth were all assessed to detemine total final costs of agents

Baseline Characteristics

 

Dinprostone (n=24)

Misoprostol (n=24)

Balloon (n=77)

 

Maternal age, years

28.87 ± 1.26 29.93 ± 1.26 29.54 ± 0.68  

Gestational age, weeks

38.6 ± 0.29 38.78 ± 0.31  38.22 ± 0.18   

Previous childbirths

0.5 ± 0.13  0.5 ± 0.14  0.46 ± 0.06   

Bishop score

2.5 ± 0.29  2.2 ± 0.21  2.54 ± 0.14   

Results

 

Dinprostone (n=24)

Misoprostol (n=24)

Balloon (n=77)

P-value 

Delivery interval, hours

Delivery within 24 hours

19.6 ± 1.6

17 (70.8%)

23.33 ± 2.31 

10 (42.7%)

25.05 ± 1.18 

36..4%)

0.04

<0.01

Oxytocin perfusion

12 (50%)

18 (75%)

47 (61%) 0.26

Vaginal delivery

17 (70.8%) 20 (83.3%) 55 (71.4%) 0.55

Neonatal admission

6 (25%) 2 (8.33%) 24 (31.2%) 0.02

Admission duration, days

2.52 ± 0.84 2.66 ± 0.7 2.96 ± 0.91 0.03
Total Cost, $ 3,075.77 ± 896.14 2,765.18 ± 495.38 3,228.02 ± 902.06 0.03

Misoprostol 25 μg tablet was the most economical method ($9.45 ± 1.52) compared with dinoprostone 10 mg vaginal insert or Cook® cervical ripening balloon ($41.67 ± 0 and $59.85 ± 0, respectively, p<0.01). 

There were no cost differences between the three methods in expenses related to delivery procedures, or in medication during the admission. Total costs in misoprostol ($2,765.18 ± 495.38) were lower than in dinoprostone or in the balloon ($3,075.77 ± 896.14 and $3,228.02 ± 902.06, respectively; p=0.03).

Adverse Events

N/A

Study Author Conclusions

Misoprostol for induction of labor had lower related costs than dinoprostone or Cook® balloon, with similar obstetrical and perinatal outcomes.

InpharmD Researcher Critique

This study did a great job in including all expenses associated with childbirth from medication and epidural costs to the employment of a midwife and the possibility of neonatal admission post-delivery. This study was conducted in Spain, but the cost data were presented in US dollars.

This study has several limitations, such as the retrospective design, small sample sizes, and the fact that no complicated patients were included. Complicated mothers and/or fetuses may increase costs substantially across the board and should be considered.



Table 3 References:
[11] Duro-Gómez J, Garrido-Oyarzún MF, Rodríguez-Marín AB, et al. What can we do to reduce the associated costs in induction of labour of intrauterine growth restriction foetuses at term? A cost-analysis study. Arch Gynecol Obstet. 2017;296(3):483-488.
Induction of Labour with a Viable Infant: A Randomised Clinical Trial Comparing Intravaginal Misoprostol and Intravaginal Dinoprostone

Design

Randomized, double-blinded trial

N=369

Objective

To compare the efficacy and safety of vaginal misoprostol with dinoprostone

Study Groups

Misoprostol (n=184)

Dinoprostone (n=185)

Methods

Inclusion criteria: singleton pregnancy, Bishop score <5, fewer than four spontaneous uterine contractions per hour

Exclusion criteria: acute fetal distress, fetal-pelvic disproportion, placenta praevia, diagnosed with breech or transverse lie, previous cesarean section

Either dinoprostone gel (2 mg) or misoprostol (50 µg) was given to patients in the posterior fornix after randomization. Misoprostol dose was repeated 6 hours after initiation if regular uterine contractions had not started. Dinoprostone gel 1 mg was also given 6 hours later if regular uterine contraction had not started. During labor, IV oxytocin was also given if infrequent contractions or arrested labor occurred.

Outcome Measures

Rate of vaginal deliveries within 24 hours, vaginal delivery rate within 12 hours, time interval from randomization to delivery

Baseline Characteristics

 

 

Misoprostol (n=184)

Dinoprostone (n=185)

 

Age (years)

29.0

29.2

 

Gestational age (weeks)

39.9

39.7

 

Bishop score <3

95 (51.6%)

93 (50.3%)

 

Nulliparas

128 (69.6%)

127 (68.7%)

 

Results

 

Misoprostol (n=184)

Dinoprostone (n=185)

Hazard Ratio or Relative Risk (95% Confidence Interval)

Vaginal Delivery within 24 h

124 (67.4%)

105 (56.8%)

RR 1.19 (1.01-1.40)

Time to delivery, min

843

1093

HR 1.46 (1.18-1.79)

Time to vaginal delivery, min

910

1128

HR 1.52 (1.21-192)

Vaginal delivery within 12 h

55 (29.9%)

37 (20.0%)

RR 1.50 (1.04-2.15)

Total costs

£2,134 ± 574

£2,202 ± 595

p=0.12

Adverse Events

Misoprostol: hyperstimulation (1.1%), tachysystole (6.5%), vaginal pain (2%), postpartum hemorrhage (9%)

Dinoprostone: hyperstimulation (2.7%), tachysystole (3.2%), vaginal pain (18%), postpartum hemorrhage (9%)

Study Author Conclusions

Vaginal misoprostol was shown to have greater efficacy compared with vaginal dinoprostone in regard to vaginal delivery within 24 hours, time to vaginal delivery, and vaginal delivery within 12 hours. There was no significant difference in cesarean section rate for fetal distress for both treatments. The median cost between misoprostol and dinoprostone was £1200 and £1212, respectively.

InpharmD Researcher Critique

The study was performed in France with a difference in health care system and cost.

Table 4 References:
[12] Rozenberg P, Chevret S, Goffinet F, et al. Induction of labour with a viable infant: a randomised clinical trial comparing intravaginal misoprostol and intravaginal dinoprostone. BJOG. 2001;108(12):1255-62.

 

A randomised controlled trial comparing low dose vaginal misoprostol and dinoprostone vaginal gel for inducing labour at term

Design

Randomized, single-blind, controlled trial

N=268

Objective

To compare the efficacy of low dose vaginal misoprostol and dinoprostone vaginal gel for induction of labor at term

Study Groups

Vaginal misoprostol (n=139)

Dinoprostone vaginal gel (n=129)

Methods

Inclusion criteria: women, singleton pregnancy at term (between 37 and 42 completed weeks of pregnancy), cephalic presentation, no significant maternal or fetal medical condition, no previous uterine surgery, parity <4 and no contraindication to prostaglandin

Exclusion criteria: Bishop score ≥8, any abnormalities of the fetal heart or any significant uterine activity 

Participants were randomized to misoprostol 25 mcg (a quarter of a 100 mcg tablet) inserted into the posterior vaginal fornix every 4 hours (maximum 6 doses) or dinoprostone vaginal gel 1-2 mg 6 hourly (maximum 3 mg in 24 hours).

Duration

July 2000 to December 2003 

Outcome Measures

Induction-to-vaginal delivery interval, requirements for oxytocin, mode of delivery, number of women delivering <24 hours, incidence of uterine contraction abnormalities, incidence of abnormal cardiotocograph (CTG) recordings, 5-minute Apgar scores, umbilical cord pH readings, analgesia requirements, admission to NICU and blood loss at delivery

Baseline Characteristics

 

Misoprostol (n=139)

Dinoprostone (n=129)

 

Age, years

28.73 ± 5.34 29.57 ± 5.19  

Parity

0.54 ± 0.73 0.60 ± 0.76  

Gravidity

1.99 ± 1.24 2.00 ± 1.19  

Gestation, days

289.02 ± 24.91 290.31 ± 9.52  

Maternal weight, kg

71.05 ± 15.28 72.37 ± 16.67  

Birthweight of baby, g

3720 ± 445 3819 ± 472  

Bishop score at induction

0-4

5-8

8+

 

86 (63)

43 (31)

8 (6) 

 

83 (65)

36 (28)

9 (7) 

 

Results

Comparison of induction-to-vaginal delivery interval, minutes (range)

 

Misoprostol (n=138) Dinoprostone (n=129) P-value
All subjects (n=267)*

971 (150-8,223)

990 (224-5,229)

0.72

Nulliparious only (n=152)

Misoprostol (n=81)

1,380 (179-8,223)

Dinoprostone (n=71)

1,390 (317-5,229)

0.48

Multiparious only (n=115)

Misoprostol (n=57)

663 (150-5,351)

Dinoprostone (n=58)

718 (224-3,330)

0.51

 *Data missing for one participant      

Outcomes in labor

 

Misoprostol (n=139) Dinoprostone (n=129)

Relative Risk (95% confidence interval)

Women delivering <24 hours

Nulliparous only (n=152)

Multiparous only (n=116)

96 (69%)

45 (56%)

51 (88%) 

88 (68%)

37 (52%)

51 (88%) 

1.01 (0.86 to 1.19)

1.07 (0.79 to 1.43)

1.00 (0.87 to 1.14) 

Requiring oxytocin augmentation

Nulliparous only (n=152)

Multiparous only (n=116)

50 (36%)

42 (52%)

8 (14%)

46 (36%)

41 (58%)

5 (9%) 

1.01 (0.73 to 1.39)

0.90 (0.67 to 1.20)

1.60 (0.56 to 4.60) 

Mode of delivery

All subjects (n=268)

Vaginal

Instrumental

Caesarean

Nulliparous only (n=152)

Vaginal

Instrumental

Caesarean

Multiparous only (n=116)

Vaginal

Instrumental

Caesarean

 

 

74 (53%)

29 (21%)

36 (26%)

 

22 (27%)

25 (31%)

34 (42%)

 

52 (90%)

4 (7%)

2 (3%)

 

 

72 (56%)

26 (20%)

31 (24%)

 

23 (32%)

20 (28%)

28 (39%)

 

49 (84%)

6 (10%)

3 (5%)

 

 

0.95 (0.77 to 1.19)

1.04 (0.65 to 1.66)

1.08 (0.71 to 1.63)

 

0.84 (0.51 to 1.37)

1.10 (0.67 to 1.80)

1.06 (0.72 to 1.57)

 

1.06 (0.92 to 1.22)

0.67 (0.20 to 2.24)

0.67 (0.12 to 3.84) 

Tachysystole

All subjects (n=263)

Nulliparous (n=147)

Multiparous (n=116)

 

19 (14%)

9 (11%)

10 (17%)

 

24 (19%)

11 (16%)

13 (22%)

 

0.72 (0.41 to 1.24)

0.69 (0.30 to 1.55)

0.77 (0.37 to 1.61)

Hyperstimulation

All subjects (n=263)

Nulliparous (n=147)

Multiparous (n=116)

 

1 (1%)

1 (1%)

0

 

4 (3%)

2 (3%)

2 (3%)

 

0.23 (0.49 to 1.31)

0.42 (0.04 to 4.52)

0.00

Abnormal cardiortocograph

All subjects (n=260)

Nulliparous (n=146)

Multiparous (n=114)

 

24 (18%)

21 (26%)

3 (5%)

 

27 (22%)

18 (27%)

9 (16%) 

 

0.80 (0.49 to 1.31)

0.96 (0.56 to 1.65)

0.33 (0.10 to 1.17)

 

Misoprostol (n=139)

Dinoprostone (n=129) Mean difference (95% CI) 

Estimated blood loss at delivery (mL)

All subjects (n=268)

Nulliparous (n=151)

Multiparous (n=116)

 

434 ± 363

534 ± 428

296 ± 170

 

419 ± 538

473 ± 333

354 ± 710

 

14 (-96 to 124)

61 (-63 to 185)

-58 (-248 to 132)

Adverse Events

N/A

Study Author Conclusions

Low dose vaginal misoprostol is as effective as dinoprostone gel for inducing labor at term.  There would be substantial cost savings, estimated at around £3.9 million per annum, for maternity services if low dose misoprostol became the agent of choice for inducing labor in the UK.

InpharmD Researcher Critique

This study was conducted in England, so the cost savings reported may not be reflected to the same amount or degree. This study excluded women with medical complications because concerns for safety were paramount, so it may not apply to all women who need labor induction. 

 

Table 5 References:
[13] Gregson S, Waterstone M, Norman I, Murrells T. A randomised controlled trial comparing low dose vaginal misoprostol and dinoprostone vaginal gel for inducing labour at term. BJOG. 2005;112(4):438-44.